PER-032-23招募中3 期
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Argenx BV
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participants can be included in the study only if all of the following criteria apply:
- •1. Has completed ARGX-113-2007
- •2. Is capable of providing signed informed consent, as described in Section 10.1.3, and
- •complying with protocol requirements
- •3. Agrees to use contraceptive measures consistent with local regulations and the following:
- •WOCBP (defined in Section 10.4.1) must have a negative urine pregnancy test at baseline before receiving IMP (Section 10.4.2.1).
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopathy.Active Idiopathic Inflammatory Myopathy (IIM)MedDRA version: 20.0Level: SOCClassification code: 10028395Term: Musculoskeletal and connective tissue disorders Class: 17CTIS2022-502851-79-00Argenx240
招募中
1 期
A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy1. Lupus Erythematosus, Cutaneous, Subacute2. Chronic Cutaneous Lupus ErythematosusMedDRA version: 20.0Level: SOCClassification code: 10040785Term: Skin and subcutaneous tissue disorders Class: 16MedDRA version: 21.1Level: PTClassification code: 10056509Term: Cutaneous lupus erythematosus Class: 100000004858MedDRA version: 21.1Level: PTClassification code: 10057903Term: Subacute cutaneous lupus erythematosus Class: 100000004858MedDRA version: 21.1Level: PTClassification code: 10057929Term: Chronic cutaneous lupus erythematosus Class: 100000004858CTIS2023-504863-17-00Biogen Idec Research Limited347
进行中（未招募）
1 期
A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: LLTClassification code 10012883Term: Diffuse lymphomaSystem Organ Class: 100000004864EUCTR2021-006049-36-NOIncyte Corporation81
进行中（未招募）
1 期
A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.EUCTR2021-006049-36-DKIncyte Corporation81
进行中（未招募）
1 期
A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: LLTClassification code 10012883Term: Diffuse lymphomaSystem Organ Class: 100000004864EUCTR2021-006049-36-FIIncyte Corporation81